These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 369693)

  • 21. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
    Rossof AH; Coltman CA; Jones SE; Talley RW
    Cancer Treat Rep; 1979; 63(9-10):1605-8. PubMed ID: 498159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Phase II study of VP-16 (capsule) in malignant lymphomas. A cooperative study].
    Sampi K; Ogawa M; Maekawa T; Takaku F; Kuraishi Y; Ota K; Hirano M; Hoshino A; Shirakawa S; Kimura I
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):314-9. PubMed ID: 3970554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.
    Ryan DH; Kopecky KJ; Head D; Gumbart CN; Grever MR; Karanes C; Weick JK; Coltman CA
    Cancer Treat Rep; 1987; 71(7-8):713-6. PubMed ID: 3475171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
    Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
    Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. m-AMSA in refractory lymphoma. A phase II trial of the Eastern Cooperative Oncology Group.
    Keller AM; Tsiatis AA; Neiman RS; Glick JH; Mann RB
    Am J Clin Oncol; 1985 Oct; 8(5):449-52. PubMed ID: 3840644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.
    Takasugi BJ; Jones SE; Robertone AB
    Cancer Treat Rep; 1984 Nov; 68(11):1399-401. PubMed ID: 6498855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group Study.
    Weick JK; Jones SE; Haut A; Fisher R; Dixon D
    Cancer Treat Rep; 1981; 65(7-8):611-4. PubMed ID: 6166373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas.
    Bajetta E; Buzzoni R; Viviani S; Villani F; Piotti P; Gasparini G; Bonadonna G
    Cancer Treat Rep; 1985 Sep; 69(9):965-9. PubMed ID: 3839714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of VM 26 (epipodophyllotoxin) in treating acute leukemias and lymphomas in the adult].
    Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vygovskaia IaI
    Probl Gematol Pereliv Krovi; 1981 Jul; 26(7):10-4. PubMed ID: 7279889
    [No Abstract]   [Full Text] [Related]  

  • 31. Results obtained with combination therapy of VM-26, natulan and prednisolone in generalized Hodgkin's disease.
    Eckhardt S; Döbrentey E; Bodrogi I
    Chemotherapy; 1975; 21(3-4):248-54. PubMed ID: 1098868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
    Kimura K; Yamada K; Yoshida T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the additive potential of teniposide and vincristine in non-Hodgkin's lymphoma. Australian and New Zealand Lymphoma Group.
    Cancer Treat Rep; 1986 Aug; 70(8):985-90. PubMed ID: 2873890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Salvage chemotherapy in resistant malignant lymphomas (author's transl)].
    Tursz T; Ben Ayed F; Droz JP; Spielmann M; Amiel JL
    Bull Cancer; 1982; 69(1):28-32. PubMed ID: 6176284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study.
    Weick JK; Jones SE; Ryan DH
    Cancer Treat Rep; 1983 May; 67(5):489-92. PubMed ID: 6687839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of a clinical study of an epipodophyllotoxin preparation (VM 26) in children with hemoblastoses].
    Kondrat'eva NA; Makhonova LA; Maiakova SA; Vialushkin BIa
    Probl Gematol Pereliv Krovi; 1981 Apr; 26(4):12-6. PubMed ID: 7015318
    [No Abstract]   [Full Text] [Related]  

  • 38. [Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].
    Parlier Y; Gorin NC; Stachowiak J; Najman A; Duhamel G
    Sem Hop; 1981 Nov 8-25; 57(41-42):1685-90. PubMed ID: 6272402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of small cell bronchogenic carcinoma with VM-26.
    Woods RL; Fox RM; Tattersall MH
    Cancer Treat Rep; 1979; 63(11-12):2011-3. PubMed ID: 230897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.